AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36478707
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl (10 μg) with 10 mg intrathecal bupivacaine
Trial: 36478707
Drug: Intravenous cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cocktail of 1 g acetaminophen, 5 mg morphine, and 100 μg fentanyl with 10 mg intrathecal bupivacaine
Trial: 33177476
Drug: Low-dose methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methotrexate (LDMTX) 10 mg
Trial: 33047449
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise associated with abdominal laser therapy (LLLT) for 50 minutes at 45%-55% of reserve heart rate
Trial: 33086652
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels <30 nmol/L in the first trimester
Trial: 33086652
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels <20 nmol/L in the first trimester
Trial: 33086652
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels <30 nmol/L in the third trimester
Trial: 32666123
Drug: Lusutrombopag 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lusutrombopag 0.75 mg for 6 days (first dose: 1.5 mg)
Trial: 32666123
Drug: Cyclosporine 400-600
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine 400-600 mg
Trial: 35933379
Drug: Lacrystim® treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacrystim® treatment (3 IPL sessions at D0, D15, and D45 with 4 shots per side at a fluence of 8 mJ/cm2)
Trial: 35933379
Drug: Lacrystim® treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacrystim® treatment
Trial: 35196668
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (chemotherapy and radiation therapy)
Trial: 33250396
Drug: Therapy program
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy program with strengthening (Group 1, n = 38)
Trial: 33250396
Drug: Therapy program
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy program without strengthening (Group 2, n = 21)
Trial: 33524052
Drug: Brucella antibodies
RxNorm normalized name: Brucella melitensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brucella antibodies by IgG ELISA
Trial: 33524052
Drug: Brucella antibodies
RxNorm normalized name: Brucella melitensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brucella antibodies by IgM ELISA
Trial: 33524052
Drug: Brucella antibodies
RxNorm normalized name: Brucella melitensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brucella antibodies by RBT
Trial: 33208303
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula (HFNC) treatment
Trial: 35999942
Drug: Repeat pulmonary
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat pulmonary rehabilitation program (twice in 12 months)
Trial: 34654584
Drug: High VRSA
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High VRSA dosage (H-VRSA)
Trial: 34654584
Drug: Low VRSA
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low VRSA dosage (L-VRSA)
Trial: 34705756
Drug: IV TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV TXA followed by oral TXA for 2 days (group 2D, n = 46)
Trial: 34705756
Drug: IV TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV TXA followed by oral TXA for 5 days (group 5D, n = 47)
Trial: 33122892
Drug: Evogliptin 5
RxNorm normalized name: alogliptin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evogliptin 5 mg once daily for 7 days (EVO)
Trial: 33122892
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of evogliptin 5 mg and pioglitazone 30 mg once daily for 7 days (EVO+PIO)
Trial: 33122892
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg once daily for 7 days (PIO)
Trial: 34516312
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of intravenous Solumedrol every 8 hours for 7 days
Trial: 35657079
Drug: Ibrutinib (560
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (560 mg, orally once daily) plus bendamustine (90 mg/m²) and rituximab (375 mg/m²)
Trial: 35657079
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus bendamustine (90 mg/m²) and rituximab (375 mg/m²)
Trial: 35675356
Drug: Cochlear implants
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear implants with additional visual cues
Trial: 35675356
Drug: Cochlear implants
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear implants alone
Trial: 34852767
Drug: Lidocaine hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine hydrochloride (1.5 mg/kg induction and 2 mg/kg/h maintenance)
Trial: 33032643
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ADT, WPRT, and SBRT boosts
Trial: 34298438
Drug: Hydrocortisone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (30 mg oral)
Trial: 33055122
Drug: Remote ischaemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote ischaemic conditioning (RIC) once daily for 30 days
Trial: 33055122
Drug: Remote ischaemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote ischaemic conditioning (RIC) twice daily for 30 days
Trial: 35775042
Drug: Dual-target group
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-target group (SASD bursa and LHBT sheath corticosteroid injection)
Trial: 35775042
Drug: Single-target group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-target group (SASD bursa corticosteroid injection alone)
Trial: 32621144
Drug: Routine interventional
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine interventional strategy in addition to optimal medical therapy
Trial: 32444296
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0.5 cm3 isotonic saline injection)
Trial: 33794664
Drug: Topical ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketorolac tromethamine 0.5%
Trial: 34130783
Drug: Rehabilitation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation treatment based on ICF-CY Core Sets
Trial: 33361100
Drug: Nitazoxanide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (500 mg, three times daily for 5 days)
Trial: 32979076
Drug: Walnut supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut supplementation (15% of total energy, ≈30–60 g/day)
Trial: 32975164
Drug: MFS features
RxNorm normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFS features (graph, expected change trajectory line, alert, treatment suggestions)
Trial: 32556354
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A injection (Group 1)
Trial: 32556354
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (Group 2)
Trial: 34351376
Drug: Oxycodone rescue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone rescue (oxycodone, 5 mg as second-line therapy)
Trial: 34351376
Drug: Ibuprofen rescue
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen rescue (ibuprofen, 600 mg as second-line therapy)
Trial: 34351376
Drug: Oxycodone rescue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone rescue
Trial: 34351376
Drug: Ibuprofen rescue
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen rescue
Trial: 34351376
Drug: Nonopioid users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonopioid users (acetaminophen only or acetaminophen and ibuprofen)
Trial: 35624408
Drug: Eliapixant 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eliapixant 10 mg
Trial: 35624408
Drug: Eliapixant 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eliapixant 50 mg
Trial: 35624408
Drug: Eliapixant 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eliapixant 200 mg
Trial: 34581911
Drug: Viloxazine extended-release
RxNorm normalized name: viloxazine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine extended-release capsules (viloxazine ER; Qelbree™) 100-600 mg/day
Trial: 34581911
Drug: Viloxazine extended-release
RxNorm normalized name: viloxazine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine extended-release capsules (viloxazine ER; Qelbree™)
Trial: 34564938
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg once daily for 180 days
Trial: 32024944
Drug: Pharmacogenetics dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenetics dosing
Trial: 34732500
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing
Trial: 32757545
Drug: As-usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As-usual treatment (Control Group)
Trial: 34348355
Drug: First-line drugs
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line drugs for neuropathic pain
Trial: 32854094
Drug: Transgenic rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transgenic rice (80 g) administered orally for 20 weeks
Trial: 32854094
Drug: Transgenic rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transgenic rice (5 g and 20 g) administered orally
Trial: 32854094
Drug: Transgenic rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transgenic rice (80 g) administered orally
Trial: 32493447
Drug: Hydroxychloroquine 200
RxNorm normalized name: hydroxychloroquine 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 200 mg tablet, 2 tablets daily for 1 to 3 months
Trial: 33361495
Drug: Multicomponent training
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent training with traditional exercise and exergaming, twice a week for 12 weeks
Trial: 34450687
Drug: Lateral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral injection technique with a high G prime filler
Trial: 34450687
Drug: Conventional technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional technique with a low G prime filler
Trial: 35099294
Drug: Closed loop
RxNorm normalized name: Povidone Iodine 7.5% Topical application Liquid [OPERAND CLOSED LOOP PVP-I SCRUB]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed loop control (CLC) insulin delivery
Trial: 33389313
Drug: 1.0-mg/kg/day Tripterygium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0-mg/kg/day Tripterygium wilfordii Hook F. (TwHF)
Trial: 33389313
Drug: 1.5-mg/kg/day Tripterygium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5-mg/kg/day Tripterygium wilfordii Hook F. (TwHF)
Trial: 34698813
Drug: Vi-polysaccharide Conjugate
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi-polysaccharide Conjugate Vaccine
Trial: 35427803
Drug: PDS 10‐mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDS 10‐mg/ml
Trial: 35427803
Drug: PDS 40‐mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDS 40‐mg/ml
Trial: 35427803
Drug: PDS 100‐mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDS 100‐mg/ml
Trial: 33217618
Drug: Monthly intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly intravitreal ranibizumab 0.5‐mg
Trial: 35288513
Drug: Resistance Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance Training (RT) + HMB supplementation (1500 mg daily)
Trial: 35288513
Drug: Education +
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education + HMB supplementation (1500 mg daily)
Trial: 33246482
Drug: PK-guided dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PK-guided dosing of hydroxyurea
Trial: 33246482
Drug: Standard weight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard weight-based dosing of hydroxyurea (20 mg/kg/day)
Trial: 35685676
Drug: Nalbuphine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 0.2 mg/kg intravenously
Trial: 35685676
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 μg/kg intravenously + Nalbuphine 0.2 mg/kg
Trial: 33413212
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no professional oral care)
Trial: 34478863
Drug: 5% topical
RxNorm normalized name: BP 5% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% topical benzoyl peroxide (BPO) gel applied for a total of 5 treatments
Trial: 34478863
Drug: Blue light
RxNorm normalized name: Ocuvite Blue Light Mini Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue light therapy (BLT), single 23‐minute treatment at 40 mW/cm2
Trial: 34478863
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BPO followed by BLT
Trial: 34866029
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with low-intensity shockwave therapy (LiST) and tadalafil
Trial: 32928237
Drug: Cisplatin-sensitized radiation
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-sensitized radiation therapy combined with pembrolizumab
Trial: 33296389
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of both measures
Trial: 35943743
Drug: Acupuncture (30-minute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (30-minute session after 50 mg/2 mL diclofenac sodium intramuscular injection)
Trial: 32425222
Drug: Chlorpromazine (CPZ)
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (CPZ) + standard treatment
Trial: 34503983
Drug: Prednisolone monotherapy
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone monotherapy (4 months)
Trial: 34503983
Drug: Prednisolone-itraconazole combination
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone-itraconazole combination (4 and 6 months)
Trial: 34536666
Drug: Therapeutic touch
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic touch (TT) for 10 minutes daily for three consecutive days
Trial: 33146811
Drug: modified endoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified endoscopic retrograde appendicitis therapy (mERAT)
Trial: 33146811
Drug: antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotic treatment
Trial: 35015806
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (20 µg/d)
Trial: 35418080
Drug: 4 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles of R-CHOP followed by 2 additional cycles of rituximab monotherapy for patients with negative interim PET/CT
Trial: 32479794
Drug: Tepotinib 500
RxNorm normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tepotinib 500 mg plus gefitinib 250 mg once daily (phase 2)
Trial: 34650619
Drug: Tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiotropium bromide powder inhalation (18 μg, inhalation, QD)
Trial: 34650619
Drug: Formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol fumarate powder inhalation (12 μg, inhalation, BID) plus ambroxol hydrochloride tablets (60 mg, oral, TID)
Trial: 33228459
Drug: Dexamethasone (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.6 mg/kg) administered on the third postoperative day with standard analgesia (ibuprofen and acetaminophen)
Trial: 33228459
Drug: Standard analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard analgesia (ibuprofen and acetaminophen) without dexamethasone
Trial: 35032643
Drug: Potassium nitrate
RxNorm normalized name: Potassium Nitrate
DrugBank: Potassium (DB14500)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potassium nitrate (KNO3) 1300 mg (12.8 mmol)
Trial: 36264446
Drug: Chinese-manufactured Glucophage®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese-manufactured Glucophage® (500 mg GIR tablet)
Trial: 36264446
Drug: French-manufactured Glucophage®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: French-manufactured Glucophage® (500 mg GIR tablet)
Trial: 32243492
Drug: Inclisiran 200
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran 200 mg single dose
Trial: 34454580
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor blockers (ARBs) at maximum tolerated daily dose
Trial: 32208960
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m2, days 1, 8, and 15, every 4 weeks)
Trial: 32208960
Drug: Paclitaxel with
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel with trastuzumab (PT; initially 8 mg/kg followed by 6 mg/kg, every 3 weeks)
Trial: 32868580
Drug: Low-dose β-hydroxybutyrate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose β-hydroxybutyrate (βHB) ketone monoester (KME; 252 mg·kg BW-1)
Trial: 32868580
Drug: High-dose β-hydroxybutyrate
RxNorm normalized name: 4-hydroxybutyric acid
DrugBank: gamma-Hydroxybutyric acid (DB01440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose β-hydroxybutyrate (βHB) ketone monoester (KME; 752 mg·kg BW-1)
Trial: 33563102
Drug: 4% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% chlorhexidine gluconate followed by alcohol-based 1% chlorhexidine gluconate sanitizer lotion
Trial: 33563102
Drug: Natural soap
RxNorm normalized name: Alba Natural Acnedote Soap Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural soap followed by alcohol-based 1% chlorhexidine gluconate sanitizer lotion
Trial: 33563102
Drug: Waterless method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waterless method (natural soap followed by alcohol-based 1% chlorhexidine gluconate sanitizer lotion)
Trial: 33563102
Drug: Two-stage method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-stage method (4% chlorhexidine gluconate followed by alcohol-based 1% chlorhexidine gluconate sanitizer lotion)
Trial: 33789001
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of triheptanoin
Trial: 33789001
Drug: Increased triheptanoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased triheptanoin dose levels
Trial: 32464489
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg per day for 6 weeks)
Trial: 35775284
Drug: 80% FiO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80% FiO2 (treatment group)
Trial: 34951042
Drug: ticagrelor‐aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ticagrelor‐aspirin
Trial: 34951042
Drug: clopidogrel‐aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clopidogrel‐aspirin
Trial: 35522139
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy including bevacizumab
Trial: 35522139
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy in patients with RAS/BRAF mutation